参考文献:
[1]Jamshed D , Mohan J C , Iyengar S S , et al. S-Amlodipine: An Isomer with Difference—Time to Shift from Racemic Amlodipine[J]. International Journal of Hypertension, 2018, 2018:1-14.
[2]J. S. Hiremath, “Te SESA-Angina Study — Safety and Efcacy of S (-) Amlodipine in Angina,” Indian Medical Gazette, 2005: 403–408, .
[3]S. Hu, Y. Zhang, J. He, and L. Du, “A Retrospective CostEfectiveness Analysis of S-Amlodipine in China,” Value in Health, 2014,17(7): A758, .
[4]董国红.观察苯磺酸氨氯地平与苯磺酸左旋氨氯地平对高血压患者短时血压变异性(BPV)影响[J].世界最新医学信息文摘,2019,19(13):137-138.
[5]邵如庆.氨氯地平治疗高血压的应用进展[J].中国城乡企业卫生,2019,34(07):78-81.
[6]赫松.苯磺酸左旋氨氯地平对比马来酸氨氯地平治疗轻/中度原发性高血压的临床效果观察[J].中国医药指南,2019,17(08):147-148.
[7]赵志刚,陈亚军.氨氯地平与左旋氨氯地平治疗轻、中度高血压病的系统评价[J].中国医院用药评价与分析,2015,15(03):318-321.
[8]陈琪瑞.用苯磺酸氨氯地平和苯磺酸左旋氨氯地平治疗高血压的效果对比[J].世界最新医学信息文摘,2019,19(40):125-127.